Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 12 Lung Neoplasms 9 Carcinoma, Hepatocellular 9 Small Cell Lung Carcinoma 8 Breast Neoplasms 6 Urinary Bladder Neoplasms 5 Triple Negative Breast Neoplasms 5 Neoplasms 5 Neoplasm Metastasis 5 Melanoma 5 Glioblastoma 5 Carcinoma, Transitional Cell 5 Ovarian Neoplasms 4 Advanced Solid Tumor 4 Stomach Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Sarcoma 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Lymphoma, Non-Hodgkin 3 Lymphoma, Follicular 3 Liver Neoplasms 3 Esophageal Neoplasms 3 Carcinoma, Renal Cell 3 Carcinoma, Neuroendocrine 3 Solid Cancer 2 Small Cell Lung Cancer Extensive Stage 2 Recurrence 2 Neuroendocrine Tumors 2 Lymphoma, Large B-Cell, Diffuse 2

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Anal Cancer Metastatic × atezolizumab × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡